Pipeline
Advancing a novel product candidate for cardiometabolic disorders
Prioritizing the development of ninerafaxstat in high value cardiometabolic indications.
Phase 2a clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and heart failure with preserved ejection fraction (HFpEF). We have initiated the Phase 2b FORTITUDE-HCM clinical trial.
ninerafaxstat
For the Treatment of Cardiometabolic Disorders